EQT

Perfuze is a neurovascular medical device company based in Galway, Ireland, founded in 2018. The company focuses on developing innovative catheter technology specifically for the treatment of acute ischemic stroke. Perfuze aims to enhance clinical outcomes and reduce procedural times through its proprietary catheter-based aspiration technology, which optimizes the efficiency of clot removal. By simplifying procedures and minimizing the need for alternative treatment methods, Perfuze seeks to provide cost-effective solutions for patients suffering from ischemic stroke.

Noema Pharma AG is a biotechnology company based in Basel, Switzerland, founded in 2019. The company focuses on developing innovative therapeutic products for orphan neurological disorders characterized by imbalanced neuronal networks. Its research and development efforts are dedicated to addressing disabling symptoms associated with conditions affecting the nervous system, such as Tuberous Sclerosis Complex, Trigeminal Neuralgia, and Tourette syndrome. By creating novel therapies, Noema Pharma aims to enhance the quality of life and improve patient outcomes for those suffering from these challenging disorders.

NUA Surgical is an award-winning startup based at the Innovation Hub in Galway, Ireland. The company has developed a patented surgical retractor designed to enhance the safety and efficiency of C-section procedures. NUA Surgical focuses on creating innovative medical devices for women's health, with a particular emphasis on improving outcomes for cesarean deliveries.

Calisen plc is a company based in Manchester, United Kingdom, that owns and manages essential energy infrastructure assets. It operates through two primary business units: Calvin Capital and Lowri Beck. Calvin Capital focuses on procuring, owning, and managing a portfolio of electricity and gas meters, primarily smart meters, for energy retailers. Meanwhile, Lowri Beck provides installation, meter reading, maintenance services, and ancillary support, such as customer service and call center operations, also on behalf of energy retailers. Calisen aims to capitalize on the UK government's initiative to roll out smart meters and is committed to supporting a cleaner and more sustainable energy sector by offering innovative services, including electric vehicle charging solutions. The company was incorporated in 2020.

Sequana Medical is a Swiss medical device company based in Zurich that specializes in developing and commercializing implantable pump systems to manage fluid balance within the body. The company's flagship product, the Alfapump System, is designed to automatically and continually remove ascites, which is excess fluid that accumulates in the abdominal cavity due to advanced liver disease, certain cancers, or congestive heart failure. This system moves the excess fluid to the bladder for natural elimination through urination. Sequana Medical's technology also has potential applications in managing pleural effusions in lung disease patients and fluid overload in those with end-stage renal disease and congestive heart failure. The company was founded in 2006 and has additional offices in Munich, Germany.

AMCS Group is an Irish company headquartered in Limerick, specializing in integrated software and technology solutions for the waste, recycling, and resource management industries. Founded in 2002 by James Martin and Austin Ryan, AMCS offers a comprehensive range of products, including RFID technology, weighing systems, and ERP software, which facilitate efficient management of operations such as bin, vehicle, and skip management. The company’s platform is designed to standardize and optimize business processes, enabling clients to reduce operating costs, enhance asset utilization, and improve customer service. AMCS Group serves a diverse clientele, including municipalities, private recycling firms, and commercial waste haulers, helping them transition towards a circular economy for better resource management and logistics.

FlixBus, operated by FlixMobility, is a notable provider of intercity travel, focusing on affordable, convenient, and environmentally-friendly transportation solutions. Since its inception in 2013, the company has established Europe's largest long-distance bus network and introduced green long-distance trains in 2018, alongside a pilot for all-electric buses in Germany and France. The platform offers travelers a sustainable alternative to private transportation, featuring amenities such as free WiFi, flexible online booking, and innovative ticketing systems. FlixBus also expanded its services to the United States in 2018, bringing its unique travel model to a broader audience. By collaborating with regional bus partners and private train companies, FlixMobility combines technological innovation with traditional transportation expertise, positioning itself as a leader in the evolving mobility landscape. As a result, FlixBus has transformed the travel experience for over 100 million people across Europe and the United States while contributing to job creation in the mobility sector.

Vico Therapeutics B.V. is a biotechnology company based in Leiden, the Netherlands, founded in 2019. The company specializes in the development of RNA modulating therapies aimed at treating rare neurological disorders. Vico Therapeutics focuses on conditions such as spinocerebellar ataxias, Huntington’s disease, and Rett syndrome, which encompass a range of hereditary and neurodevelopmental disorders. By discovering and developing innovative therapies, the company aims to address significant unmet medical needs in the central nervous system, providing new treatment options for patients and healthcare professionals.

Binx Health Limited is an in vitro diagnostics company based in Trowbridge, United Kingdom, founded in 2005. The company specializes in developing diagnostic instruments and disposable cartridge systems for decentralized laboratory and point-of-care settings. Its flagship product, the binx io platform, is the first FDA-cleared, CLIA-waived system for detecting chlamydia and gonorrhea in both males and females, delivering results comparable to central laboratory performance within approximately thirty minutes. Binx Health aims to enhance healthcare access by addressing traditional barriers and extending outreach through its point-of-care diagnostic solutions. The company also focuses on providing rapid polymerase chain reaction (PCR)-based results and a comprehensive digital program that includes evidence-based testing, counseling, treatment, and follow-up services. Binx Health has established a strategic partnership with Sherlock Biosciences, further strengthening its commitment to improving community health outcomes.

Onward is a medical technology company focused on developing therapies aimed at enabling functional recovery for individuals with spinal cord injuries. The company is creating an Implantable Neuro-stimulation System (INS) that features real-time motion feedback and utilizes training tools for rehabilitation. Onward has developed two platforms for neurostimulation: ARCIM, an implantable system, and ARCEX, a non-invasive transcutaneous system. To establish its customer base, Onward has targeted the United States and four European markets, namely Germany, France, the United Kingdom, and the Netherlands.

Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly focusing on antibody-drug conjugates (ADCs). The company aims to create transformative chemotherapeutic medications that are tailored to combat cancer and chronic diseases. By integrating proprietary technologies with disease-specific biology, Tubulis develops unique protein-drug combinations that enable clinicians to treat patients while minimizing the adverse effects typically associated with traditional chemotherapy. Through its innovative approach, Tubulis seeks to improve therapeutic outcomes and enhance the safety of cancer treatments.

Phagenesis Limited is a medical device company based in Manchester, United Kingdom, founded in 2007. It focuses on developing innovative technology to treat dysphagia, a condition often associated with stroke and brain injuries that impairs safe swallowing. The company's flagship product, Phagenyx, consists of a base station that delivers targeted electrical stimulations to patients while recording and storing their information, and a catheter that is introduced through the nose to stimulate the pharynx. This approach leverages the brain’s neuroplasticity, enabling patients to relearn essential swallowing functions that may have been lost due to brain damage. Phagenesis aims to improve the recovery process for stroke patients in acute care settings by utilizing a method developed by Prof. Shaheen Hamdy of the University of Manchester, which has been validated through publication in reputable scientific and medical journals.

InstaVolt Ltd is a UK-based company that specializes in the development, construction, ownership, and operation of electric vehicle (EV) charging stations. Incorporated in 2016 and headquartered in Basingstoke, InstaVolt is committed to enhancing the accessibility and convenience of EV charging across the country. The company installs and maintains rapid charging units at various locations, including retail and food service sites, allowing landowners to generate rental income while providing EV drivers with efficient charging options. InstaVolt operates on an open charger model, enabling users to access charging points on a pay-as-you-go basis without the need for subscriptions or membership cards. With a focus on improving air quality and reducing carbon emissions, InstaVolt aims to alleviate range anxiety, a significant barrier to EV adoption, by ensuring that rapid charging points are readily available throughout the UK.

Vico Therapeutics B.V. is a biotechnology company based in Leiden, the Netherlands, founded in 2019. The company specializes in the development of RNA modulating therapies aimed at treating rare neurological disorders. Vico Therapeutics focuses on conditions such as spinocerebellar ataxias, Huntington’s disease, and Rett syndrome, which encompass a range of hereditary and neurodevelopmental disorders. By discovering and developing innovative therapies, the company aims to address significant unmet medical needs in the central nervous system, providing new treatment options for patients and healthcare professionals.

AgomAb Therapeutics N.V., based in Gent, Belgium, specializes in the development of molecular therapies aimed at regenerating damaged tissues. The company focuses on creating agonistic monoclonal antibodies, known as agomAbs, which are designed to stimulate molecular and cellular repair mechanisms. These therapies have the potential to restore organ function in patients suffering from fibrotic, inflammatory, autoimmune, and degenerative diseases. AgomAb targets biologically validated pathways, including Transforming Growth Factor β and Hepatocyte Growth Factor, while employing specialized capabilities in organ-specific small molecules and high-affinity antibodies. The company boasts a diversified clinical pipeline addressing various fibrotic conditions and possesses comprehensive research and development expertise, alongside a strong track record in business development.

Xeltis AG, established in 2006, is a clinical-stage medical device company based in Zurich, Switzerland, with additional operations in the Netherlands and the USA. The company specializes in developing bio-absorbable heart valves and blood vessels using a proprietary polymer-based technology. Xeltis' RestoreX platform enables the body's natural healing system to develop tissue that replaces the implant, forming a new functional valve or vessel. The company's restorative devices include implantable small diameter blood vessels for hemodialysis and coronary artery bypass graft (CABG) surgery, as well as pulmonary heart valves, with ongoing clinical trials. Xeltis has raised funding from various venture capital firms and European institutions, including a €30 million round in 2021.

IntegrityNext is a Munich-based company founded in 2016 by Martin Berr-Sorokin that specializes in supply chain compliance and sustainability monitoring. The company offers a cloud-based platform that enables businesses to oversee their suppliers' compliance with regulatory requirements, thereby reducing risk. Its platform automates the collection of supplier self-assessments and certificates, while also monitoring social media for potential malpractice and reputational threats. With features such as automated risk alerts, a pre-built supplier questionnaire, and a real-time dashboard, IntegrityNext assists small and medium-sized enterprises in translating complex compliance data requirements from international regulations into effective processes and systems. This comprehensive approach to supply chain compliance supports organizations in achieving greater transparency and accountability in their operations.

Xeltis AG, established in 2006, is a clinical-stage medical device company based in Zurich, Switzerland, with additional operations in the Netherlands and the USA. The company specializes in developing bio-absorbable heart valves and blood vessels using a proprietary polymer-based technology. Xeltis' RestoreX platform enables the body's natural healing system to develop tissue that replaces the implant, forming a new functional valve or vessel. The company's restorative devices include implantable small diameter blood vessels for hemodialysis and coronary artery bypass graft (CABG) surgery, as well as pulmonary heart valves, with ongoing clinical trials. Xeltis has raised funding from various venture capital firms and European institutions, including a €30 million round in 2021.

va-Q-tec is a high-tech company established in 2001, specializing in innovative insulation solutions, particularly through vacuum insulation panels (VIPs). The company's products are designed to enhance energy efficiency and are environmentally friendly, making them suitable for various applications. va-Q-tec's technology significantly reduces energy costs in diverse sectors, including the transportation of pharmaceutical products, refrigeration and freezing appliances, construction, and automotive and aerospace industries. The company operates through several segments, with a strong presence in Germany and across the European Union. Its customer base spans multiple industries, including healthcare, logistics, appliances and food, construction, and technical sectors.

Cardiac Dimensions, Inc. is a medical device company focused on developing innovative minimally invasive treatments for heart failure and associated cardiovascular issues. Founded in 2000 and headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany, the company is known for its Carillon Mitral Contour System. This permanent implant is designed specifically for the treatment of functional mitral regurgitation, utilizing a catheter-based approach to reshape the mitral valve and effectively reduce regurgitation. By providing a non-surgical option for patients, Cardiac Dimensions aims to improve outcomes for those suffering from heart-related conditions.

Founded in 1933, the Saur Group is the third largest player in the French water distribution and waste water management market. In addition to its core activity, the company has also developed into municipal waste collection and treatment, and also certain ancillary services to local authorities.

SHL Medical AG specializes in the design, development, and manufacturing of advanced drug delivery systems, including auto-injectors, pen injectors, and inhaler systems. Founded in 1989 and headquartered in Zug, Switzerland, the company serves pharmaceutical and biotech firms around the globe. In addition to its core product offerings, SHL Medical provides comprehensive services such as final assembly, labeling, and packaging. The company is committed to maintaining high-quality standards and adhering to strict regulatory requirements, ensuring that it delivers innovative and reliable solutions tailored to meet the needs of its clients.

Storytel is a leading provider of audiobook and e-book streaming services, offering unlimited access to a diverse range of titles across more than 20 markets. Founded in 2005 and headquartered in Sweden, the company operates under the Storytel and Mofibo brands, providing users with the ability to explore a wide array of genres, including detective stories, novels, and biographies, in multiple languages such as Swedish, English, Arabic, Danish, and Finnish. Storytel also has a significant publishing division that includes several established publishing houses, such as Norstedts, Massolit, and B. Wahlstrom, focusing on both adult and children's literature. The company has expanded its services internationally, with operations in countries like Denmark, Norway, the Netherlands, and the USA, positioning itself as a prominent player in the subscription-based audiobook and e-book market.

eTheRNA Immunotherapies NV is a Belgium-based biotechnology company that specializes in the development of mRNA-based immunotherapies. Founded in 2013 and located in Niel, the company focuses on harnessing the immune system's dendritic cells to create treatments for melanoma, triple-negative breast cancer, and infectious diseases. eTheRNA has developed innovative TriMix technology that enhances the immune response, enabling patients to better combat these diseases. The company aims to be a leader in nucleic acid-based medicines, collaborating with partners to facilitate the creation of new drugs and improve patient outcomes. Additionally, eTheRNA has established a strategic partnership with China Grand Pharmaceutical and Healthcare Holdings Limited to further its mission.

FundamentalVR have been working with leading pharmaceutical companies to combine virtual and mixed reality with haptic feedback using their ‘FeelRealVR’ platform to create simulated surgical procedures to help educate and train healthcare professionals. The company works at the nexus of haptics, machine learning, and immersive technologies (XR). FundamentalVR was established in 2012 by Chris Scattergood in London, England.

InstaVolt Ltd is a UK-based company that specializes in the development, construction, ownership, and operation of electric vehicle (EV) charging stations. Incorporated in 2016 and headquartered in Basingstoke, InstaVolt is committed to enhancing the accessibility and convenience of EV charging across the country. The company installs and maintains rapid charging units at various locations, including retail and food service sites, allowing landowners to generate rental income while providing EV drivers with efficient charging options. InstaVolt operates on an open charger model, enabling users to access charging points on a pay-as-you-go basis without the need for subscriptions or membership cards. With a focus on improving air quality and reducing carbon emissions, InstaVolt aims to alleviate range anxiety, a significant barrier to EV adoption, by ensuring that rapid charging points are readily available throughout the UK.

Perfuze is a neurovascular medical device company based in Galway, Ireland, founded in 2018. The company focuses on developing innovative catheter technology specifically for the treatment of acute ischemic stroke. Perfuze aims to enhance clinical outcomes and reduce procedural times through its proprietary catheter-based aspiration technology, which optimizes the efficiency of clot removal. By simplifying procedures and minimizing the need for alternative treatment methods, Perfuze seeks to provide cost-effective solutions for patients suffering from ischemic stroke.

ViCentra B.V., based in Utrecht, the Netherlands, specializes in the development of medical devices, particularly for diabetes management. The company focuses on creating user-friendly and aesthetically pleasing products that aim to enhance the overall experience for individuals managing their health. ViCentra emphasizes the importance of excellent customer experiences and approaches product design with the belief that simplicity and effectiveness lead to better health outcomes. In addition to its operations in the Netherlands, ViCentra also has a presence in the UK, where it continues to innovate in the field of medical devices through dedicated research and development efforts.

AviadoBio is a biotechnology company focused on developing transformative gene therapies for neurodegenerative disorders, specifically targeting diseases such as frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company leverages innovative research from King’s College London and the UK Dementia Research Institute to create its therapeutic platform. By integrating a deep understanding of brain biology with proprietary gene therapies, AviadoBio aims to effectively address the challenges of delivering treatments to the appropriate areas within the nervous system. The ultimate goal is to enhance the therapeutic potential of gene therapy, potentially halting or even reversing the progression of these debilitating conditions, thereby improving the quality of life for affected individuals.

Egle Therapeutics SAS is a biotechnology company founded in 2020 and based in Paris, France. The company specializes in developing immunotherapies aimed at targeting immune suppressor regulatory T-cells (Tregs) to address oncology and autoimmune diseases. Egle Therapeutics is focused on its proprietary pipeline, which includes a series of computationally designed IL-2 variants designed to modulate Tregs by either engaging or disengaging them from tumor environments. Through its innovative approach to Treg modulation, the company aims to enable healthcare professionals to develop new therapies that effectively target these immune suppressor cells, potentially transforming treatment options for cancer and other diseases.

Storytel is a leading provider of audiobook and e-book streaming services, offering unlimited access to a diverse range of titles across more than 20 markets. Founded in 2005 and headquartered in Sweden, the company operates under the Storytel and Mofibo brands, providing users with the ability to explore a wide array of genres, including detective stories, novels, and biographies, in multiple languages such as Swedish, English, Arabic, Danish, and Finnish. Storytel also has a significant publishing division that includes several established publishing houses, such as Norstedts, Massolit, and B. Wahlstrom, focusing on both adult and children's literature. The company has expanded its services internationally, with operations in countries like Denmark, Norway, the Netherlands, and the USA, positioning itself as a prominent player in the subscription-based audiobook and e-book market.

Cardior Pharmaceuticals GmbH is a biotechnology company based in Hanover, Germany, founded in 2016. The company specializes in developing non-coding RNA-based therapeutics aimed at treating and preventing heart disease, which is the leading cause of death in the western world. Its primary focus is on CDR-132X, an oligonucleotide-based inhibitor that targets a critical microRNA responsible for pathological changes in the heart resulting from stress or injury. Through its innovative approach, Cardior Pharmaceuticals seeks to address significant unmet medical needs in cardiovascular health.

PRO Unlimited Inc. specializes in developing contingent workforce management solutions tailored for Global and Fortune 500 companies. Founded in 1991 and headquartered in Boca Raton, Florida, the company offers a vendor-neutral Managed Services Program that assists clients in effectively managing the procurement, selection, engagement, and tracking of various contingent workers, including independent contractors, consultants, and freelancers. PRO Unlimited also provides a software-as-a-service platform known as Vendor Management System (VMS), which centralizes the management of contingent workforce activities, statement of work engagements, and independent contractor utilization, thereby enhancing quality control, cost management, and compliance. Additionally, its RatePoint application delivers on-demand rate and hiring intelligence for professional contingent positions. The company's solutions address critical challenges such as supplier management, worker classification, lifecycle tracking, and 1099 management. With locations in the United Kingdom, Japan, California, New York, and Hong Kong, PRO Unlimited is well-positioned to meet the evolving needs of the contingent workforce marketplace.

Mollie is a technology-driven payments platform based in Amsterdam, founded in 2004. It simplifies the integration of payment solutions for online merchants, processing transactions for over 50,000 clients. The platform supports a wide array of local payment methods, including major credit cards, PayPal, and various local banking options, as well as cryptocurrencies. Mollie's application features one-click payments, fraud monitoring, multicurrency support, daily settlement management, and real-time accounting, enabling businesses to streamline their operations and enhance revenue management. The company prioritizes innovation and reliability, aiming to make online payments straightforward and efficient for merchants.

Parcel2Go is the UK's largest online parcel delivery service, offering a comprehensive range of courier services for both home and business users. The company operates a parcel delivery comparison platform that provides an alternative to traditional postal services. By collaborating with major partners such as FedEx, TNT, UPS, and Hermes, Parcel2Go enables customers to send packets and parcels of various sizes to destinations within the UK and internationally. Their platform allows users to manage orders online, track shipments, and access affordable delivery options, streamlining the shipping process for individuals and businesses alike.

Solarpack is an independent solar photovoltaic power producer that specializes in the development and operation of large-scale solar projects. Established in 2005 and headquartered in Getxo, Vizcaya, Spain, the company offers a comprehensive range of services, including financing, construction, and management of utility-scale solar plants. With a total operational capacity of 160 MW across 13 plants and asset management services for an additional 302 MW, Solarpack has a diversified geographical presence, employing over 140 people in 10 countries. The company aims to contribute to sustainable energy infrastructure while fostering social development within the communities it serves by creating economic value and promoting quality employment through its initiatives.

Binx Health Limited is an in vitro diagnostics company based in Trowbridge, United Kingdom, founded in 2005. The company specializes in developing diagnostic instruments and disposable cartridge systems for decentralized laboratory and point-of-care settings. Its flagship product, the binx io platform, is the first FDA-cleared, CLIA-waived system for detecting chlamydia and gonorrhea in both males and females, delivering results comparable to central laboratory performance within approximately thirty minutes. Binx Health aims to enhance healthcare access by addressing traditional barriers and extending outreach through its point-of-care diagnostic solutions. The company also focuses on providing rapid polymerase chain reaction (PCR)-based results and a comprehensive digital program that includes evidence-based testing, counseling, treatment, and follow-up services. Binx Health has established a strategic partnership with Sherlock Biosciences, further strengthening its commitment to improving community health outcomes.

Onward is a medical technology company focused on developing therapies aimed at enabling functional recovery for individuals with spinal cord injuries. The company is creating an Implantable Neuro-stimulation System (INS) that features real-time motion feedback and utilizes training tools for rehabilitation. Onward has developed two platforms for neurostimulation: ARCIM, an implantable system, and ARCEX, a non-invasive transcutaneous system. To establish its customer base, Onward has targeted the United States and four European markets, namely Germany, France, the United Kingdom, and the Netherlands.

Neurent Medical Limited is a medical device company based in Galway, Ireland, founded in 2015 by Brian Shields and David Townley. The company specializes in developing non-surgical treatments for inflammatory sino-nasal diseases, specifically focusing on chronic rhinitis. Neurent Medical offers a single-use, minimally invasive device designed for ENT surgeons, which utilizes a hand-held radio-frequency mechanism. This device is introduced through the nostrils into the nasal cavity under direct endoscopic visualization, where it deploys a microelectrode array to deliver targeted energy. This intervention interrupts the autonomic function of the mucosal structures in the nasal cavities, effectively reversing the inflammatory cascade. By enabling treatment in an office setting, Neurent Medical aims to eliminate the complications and costs typically associated with traditional surgical procedures for rhinitis.

NewAmsterdam Pharma, established in 2019 and headquartered in Naarden, the Netherlands, is a late-stage biopharmaceutical company dedicated to improving patient care in cardio-metabolic disease populations. The company's primary focus is the development of transformative therapies, with its lead product, obicetrapib, being a next-generation, oral, low-dose CETP inhibitor designed to lower LDL-C levels more effectively than current treatments, particularly for patients with statin intolerance or Arteriosclerotic Cardiovascular Disease/Familial Hypercholesterolemia (ASCVD/FH) on maximally-tolerated statin therapy.

Molslinjen is a privately held company specializing in ferry services between Jutland and the island of Zealand. The company operates domestic ferry lines and floating bridges, providing essential marine transportation services. Utilizing a fleet of catamaran ferries, Molslinjen facilitates efficient and comfortable travel for passengers, as well as vehicles such as cars, trucks, and buses. Its large car decks allow for easy boarding and disembarking, enhancing the overall travel experience. By prioritizing speed and convenience, Molslinjen plays a vital role in connecting regions and supporting local transportation needs.

Cardiac Dimensions, Inc. is a medical device company focused on developing innovative minimally invasive treatments for heart failure and associated cardiovascular issues. Founded in 2000 and headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany, the company is known for its Carillon Mitral Contour System. This permanent implant is designed specifically for the treatment of functional mitral regurgitation, utilizing a catheter-based approach to reshape the mitral valve and effectively reduce regurgitation. By providing a non-surgical option for patients, Cardiac Dimensions aims to improve outcomes for those suffering from heart-related conditions.

Idealista operates an online property portal that serves agents and private individuals in Spain, Italy, and Portugal. The platform functions as a digital real estate marketplace, providing buyers and sellers with essential real-time information to facilitate property transactions. By offering a user-friendly interface, Idealista helps alleviate the challenges associated with finding a home, thus supporting millions of users in their real estate endeavors. Additionally, the company allows property owners to advertise their listings through a subscription model, enabling them to reach a broader audience while accessing valuable market insights.

Colisée is a prominent entity in the health care sector, specializing in the care and well-being of elderly individuals. The company operates over 90 retirement homes and nearly 70 home-based service agencies across France, Italy, and Spain. By focusing on both nursing home and home care services, Colisée provides essential daily care to residents and patients, as well as support for their families. With a workforce exceeding 6,700 employees, the organization is committed to delivering quality care tailored to the needs of the aging population.

Lumeon Ltd. is a digital health company based in London, United Kingdom, specializing in care pathway management solutions for the healthcare sector. Founded in 2005 and previously known as Qinec Ltd., Lumeon offers a cloud-based platform called Care Pathway Manager, which provides a comprehensive, real-time view of the patient journey from referral to outcome. The platform enables healthcare providers to unify clinical and administrative workflows, automate tasks, and deliver measurable care, addressing the underlying systems that drive healthcare transformation. Lumeon's clientele includes some of Europe's leading healthcare providers, such as BUPA and Nuffield Health, reflecting its position as a key player in the market. The company employs over 90 professionals dedicated to enhancing patient care through effective management and analysis of healthcare pathways.

Vico Therapeutics B.V. is a biotechnology company based in Leiden, the Netherlands, founded in 2019. The company specializes in the development of RNA modulating therapies aimed at treating rare neurological disorders. Vico Therapeutics focuses on conditions such as spinocerebellar ataxias, Huntington’s disease, and Rett syndrome, which encompass a range of hereditary and neurodevelopmental disorders. By discovering and developing innovative therapies, the company aims to address significant unmet medical needs in the central nervous system, providing new treatment options for patients and healthcare professionals.

ViCentra B.V., based in Utrecht, the Netherlands, specializes in the development of medical devices, particularly for diabetes management. The company focuses on creating user-friendly and aesthetically pleasing products that aim to enhance the overall experience for individuals managing their health. ViCentra emphasizes the importance of excellent customer experiences and approaches product design with the belief that simplicity and effectiveness lead to better health outcomes. In addition to its operations in the Netherlands, ViCentra also has a presence in the UK, where it continues to innovate in the field of medical devices through dedicated research and development efforts.

Cybin is a biopharmaceutical company dedicated to advancing research and development in psychedelic and medicinal mushrooms. It focuses on creating safe and effective therapeutics for mental health issues, with an emphasis on psilocybin-based products. The company is actively launching these products in jurisdictions where they are permitted and is engaged in clinical studies across North America and other regions. Through strategic partnerships with academic and institutional entities, Cybin seeks to develop novel compounds and delivery mechanisms, aiming to provide innovative treatments for various psychiatric and neurological conditions.

Freepik Company, founded in 2010 and based in Málaga, Spain, provides an innovative digital platform that caters to the needs of designers and creative professionals. The company offers a vast library of over 250 million visual assets, including illustrations, photos, icons, mock-ups, and presentation templates, making it easier for users to access high-quality graphic resources for various applications such as websites, advertisements, and presentations. With a strong focus on integrating advanced generative AI technology, Freepik enhances content creation by enabling users to quickly transform ideas into audiovisual materials. The platform serves over 100 million users, including nearly 800,000 subscribers, and is committed to adapting to emerging design trends and technological advancements, thereby redefining the landscape of digital creativity.

Kiadis Pharma N.V. is a clinical-stage biopharmaceutical company based in Amsterdam, the Netherlands, specializing in the development of cell-based immunotherapy products for blood cancers and inherited blood disorders. The company is currently advancing its product pipeline, which includes K-NK002, an adjunctive immunotherapeutic in Phase II trials for blood cancer patients undergoing haploidentical hematopoietic stem cell transplants, and K-NK003, which is in Phase I/II trials for patients with acute myeloid leukemia who are relapsed or refractory. Additionally, Kiadis Pharma is developing K-NK00X, a preclinical NK-cell therapy candidate aimed at treating various solid tumors. The company is engaged in collaborative efforts with multiple institutions to explore innovative treatments, including a combination of a monoclonal antibody and natural killer cells for COVID-19. Established in 1997, Kiadis Pharma addresses critical unmet medical needs in oncology through its innovative therapeutic approaches.

FoRx Therapeutics AG is a biotechnology company based in Basel, Switzerland, founded in 2019. The company is dedicated to developing innovative therapeutics for cancer treatment, specifically targeting key molecular pathways associated with DNA replication stress. By focusing on these novel pathways, FoRx aims to create first-in-class compounds that provide a new approach to targeted anticancer therapies. Through its research and development efforts, FoRx Therapeutics seeks to advance the healthcare industry's capabilities in combating cancer effectively.

Deutsche Glasfaser Holding GmbH, founded in 2012 and based in Borken, Germany, specializes in the planning, construction, and operation of fiber optic networks aimed at rural and suburban areas. As a pioneering provider in the industry, the company focuses on delivering fiber-to-the-home (FTTH) connections to private households, businesses, and public institutions. By collaborating closely with municipalities, Deutsche Glasfaser aims to facilitate nationwide broadband expansion, contributing significantly to Germany's digital progress. The company is recognized for its innovative and cost-efficient approaches to fiber optic deployment, positioning itself as a technology leader in the market. With substantial backing from experienced investors, Deutsche Glasfaser has emerged as one of the strongest providers in Germany's telecommunications landscape.

SHL Medical AG specializes in the design, development, and manufacturing of advanced drug delivery systems, including auto-injectors, pen injectors, and inhaler systems. Founded in 1989 and headquartered in Zug, Switzerland, the company serves pharmaceutical and biotech firms around the globe. In addition to its core product offerings, SHL Medical provides comprehensive services such as final assembly, labeling, and packaging. The company is committed to maintaining high-quality standards and adhering to strict regulatory requirements, ensuring that it delivers innovative and reliable solutions tailored to meet the needs of its clients.

iSTAR Medical SA is a Belgian company specializing in the development of innovative ophthalmic implants aimed at treating glaucoma. Founded in 2010 as a spinout of Healionics Corporation, the company has established itself in the field with its flagship product, the STARflo glaucoma implant. This non-degradable, precision-pore device functions as a micro-porous drainage system that reduces intraocular pressure by enhancing the eye’s natural uveoscleral outflow. iSTAR Medical's offerings also include STARflo PLUS and STARflo MINI surgical therapies, which incorporate anti-fibrotic and anti-inflammatory properties to improve patient outcomes. The company operates from its eco-friendly R&D and manufacturing facility in CREALYS Scientific Park near Namur, Belgium, and distributes its products through various international partners across Europe and Asia. iSTAR Medical is committed to providing advanced and effective treatment alternatives for glaucoma patients, with its devices designed to limit inflammation and fibrosis while promoting bio-integration with surrounding tissues.

AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.

Imcyse SA is a clinical-stage biopharmaceutical company based in Liège, Belgium, specializing in innovative immunotherapeutic solutions aimed at treating severe chronic autoimmune diseases. Founded in 2010, Imcyse is pioneering a unique technology platform that employs Imotopes™, specifically modified peptides that target immune cells responsible for organ damage. This approach facilitates the generation of cytolytic CD4 T-cells, which selectively eliminate antigen-presenting cells and autoantigen-specific lymphocytes, thereby addressing diseases with limited treatment options. The company has shown proof of concept across various indications and has completed its initial clinical trial for type 1 diabetes, yielding promising outcomes. In addition to type 1 diabetes, Imcyse is actively developing a pipeline of therapies for multiple autoimmune diseases, aiming to provide effective treatment while preserving overall immune defense.

Snipr Biome ApS is a biotechnology company based in Copenhagen, Denmark, that focuses on developing innovative CRISPR technology for the treatment of microbial diseases. Incorporated in 2017, the company aims to revolutionize healthcare by utilizing a programmable approach to the adaptive immune system, enabling the targeted elimination of hazardous bacteria based on their specific DNA sequences. Snipr Biome's novel medicines are designed to provide health professionals with effective tools for microbiome engineering, allowing for selective targeting and destruction of harmful bacteria in vivo.

WS Audiology A/S is a manufacturer and distributor of hearing instruments and audiological solutions, headquartered in Lynge, Denmark. Established in 2019 through a partnership between Sivantos and Widex, the company aims to enhance hearing care for individuals with hearing needs. Its product offerings include a comprehensive range of hearing aids, such as receiver-in-the-ear devices, assistive listening devices, and solutions for single-sided deafness. Additionally, WS Audiology provides accessories like hearing aid batteries, remote controls, and electronic drying stations. The company's diverse product spectrum caters to various price categories, ensuring that those with hearing loss have access to effective solutions for improved hearing and understanding.

Atlantic Therapeutics Limited is a medical technology company based in Galway, Ireland, with additional offices in London, Paris, and Salem. Established in 2013, the company specializes in the manufacture and distribution of medical devices designed for pelvic floor muscle strengthening and nerve stimulation. Its key products include Innovotherapy, a device aimed at enhancing pelvic floor muscle function, and INNOVO, a wearable device specifically targeting stress urinary incontinence by addressing its underlying causes. Atlantic Therapeutics distributes its products through a network of distributors across Ireland, the United Kingdom, France, Germany, and the Middle East. The company operates as a subsidiary of Bio-Medical Research Limited.

Lumeon Ltd. is a digital health company based in London, United Kingdom, specializing in care pathway management solutions for the healthcare sector. Founded in 2005 and previously known as Qinec Ltd., Lumeon offers a cloud-based platform called Care Pathway Manager, which provides a comprehensive, real-time view of the patient journey from referral to outcome. The platform enables healthcare providers to unify clinical and administrative workflows, automate tasks, and deliver measurable care, addressing the underlying systems that drive healthcare transformation. Lumeon's clientele includes some of Europe's leading healthcare providers, such as BUPA and Nuffield Health, reflecting its position as a key player in the market. The company employs over 90 professionals dedicated to enhancing patient care through effective management and analysis of healthcare pathways.

Founded in 1933, the Saur Group is the third largest player in the French water distribution and waste water management market. In addition to its core activity, the company has also developed into municipal waste collection and treatment, and also certain ancillary services to local authorities.

Veritas Petroleum Services is a global provider of testing, inspection, and advisory services, operating five laboratories strategically located in the Netherlands, Singapore, Houston, Fujairah, and Manchester. The company specializes in fuel quality testing, bunker quantity surveys, oil condition monitoring, and transformer oil testing, among other services. By offering these solutions, Veritas Petroleum Services assists clients in the marine, power, and renewable sectors to optimize their operational performance. The company focuses on helping its customers improve fuel management, reduce fuel costs, enhance operational efficiency, and comply with environmental regulations.

Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in developing innovative cancer treatments targeting DNA damage response (DDR) pathways. Founded in 2016, the company is dedicated to creating first-in-class therapies that selectively kill cancer cells by exploiting their reliance on DDR mechanisms. Artios’ product pipeline includes a range of promising candidates, such as a therapy that targets DNA polymerase theta, a protein involved in DNA repair processes, and another program focusing on a novel DDR target. The company collaborates with prominent research organizations, including Cancer Research Technology, to enhance its development efforts and leverage expertise in DNA repair. Artios is led by a skilled team with extensive experience in drug discovery, positioning it to advance its next-generation DDR programs and contribute significantly to the field of cancer treatment.

SUSE is a global leader in open source solutions, providing reliable and enterprise-grade software to a diverse range of industries, including automotive, telecom, banking, healthcare, manufacturing, retail, and technology. With a strong focus on Enterprise Linux, Kubernetes Management, and Edge solutions, SUSE supports mission-critical workloads for over 60% of the Fortune 500 companies. The company emphasizes collaboration with partners and communities to empower customers to innovate across various environments, from data centers to the cloud and edge. SUSE offers consulting, blended services, and training and certification, primarily generating revenue from subscriptions. Headquartered in Nuremberg, Germany, SUSE employs nearly 2,000 people globally and derives a significant portion of its revenue from North America.

Azelis Group is a specialty chemicals distributor and innovation service provider that caters to the specialty chemicals and food ingredients industries. The company operates through several geographic segments, including EMEA, which encompasses Europe, the Middle East, and Africa; the Americas, which includes the United States, Canada, Mexico, and parts of South America; and Asia-Pacific, covering various countries in Asia and the Pacific region. Azelis leverages its extensive local knowledge and an international structure to offer a diverse range of products and services. The company emphasizes high levels of technical support and customized solutions to meet the specific needs of its clients. Its operations are supported by a corporate service center and headquarters located in Belgium.

MediFox GmbH, founded in 1994 and headquartered in Hildesheim, Niedersachsen, Germany, specializes in developing software solutions for ambulatory nursing care service providers and nursing care homes. The company offers enterprise system software designed to support outpatient care services, inpatient facilities, and therapeutic practices. MediFox's software encompasses essential services such as resource and route planning, care and support documentation, management information systems, and administration services, including billing and factoring. By providing these tools, MediFox enables care providers to enhance their organizational structure and streamline their processes in response to evolving industry needs.

Dojo is a financial technology company that specializes in providing card payment solutions to small and medium-sized businesses in the UK and Ireland. The company offers a range of services, including contactless card machines, online payment systems, and integrated solutions, allowing over 100,000 businesses to accept payments in-store, online, via phone, and on the move. Founded in 2008 and based in London, Dojo focuses on delivering flexible and efficient payment processing options tailored to the needs of its clients. The company's offerings aim to enhance the payment experience for both merchants and their customers, thereby facilitating smoother transactions across various platforms.

BBS Automation GmbH is a provider of automation solutions and engineering services, specializing in the design, development, manufacturing, and installation of automated assembly and testing systems. The company serves a diverse range of industries, including automotive, aerospace, life sciences, consumer goods, electronic devices, energy storage, and renewable energy. BBS Automation also offers leak detection, build-to-print services, and winding technology solutions, along with training and after-sales support. With nearly 550 employees, the company operates production sites in Germany, China, Malaysia, and the United States, partnering with prominent global clients. Founded in 1891 and headquartered in Garching bei München, Germany, BBS Automation is committed to delivering flexible and high-quality automation solutions for complex manufacturing and testing processes.

Simplify Medical, Inc. is a medical device company specializing in the design, development, manufacturing, and marketing of cervical and lumbar artificial discs intended for spinal use. Founded in 2013 and based in Sunnyvale, California, it offers innovative products such as the Simplify Disc, a non-metallic, MRI-compatible artificial cervical disc that preserves motion while allowing for full diagnostic imaging without the need for traditional CT scans. This technology minimizes patient exposure to ionizing radiation and is tailored for skeletally mature patients undergoing reconstruction at one level from C3 to C7 following discectomy procedures. Simplify Medical markets its products through distributors in the United Kingdom, Germany, and other international markets. The company was previously known as Simplify Delaware, Inc. before rebranding in February 2015.

Studienkreis is one of Germany's largest providers of professional tutoring services, operating nearly 1,000 tuition schools nationwide since its establishment in 1974. The company specializes in providing offline and digital tutoring aimed at primary and secondary school students, offering support across all major subjects through its proprietary teaching materials and scientifically backed learning methodologies. Studienkreis focuses on helping children and adolescents enhance their academic performance and achieve consistently good grades. In addition to addressing specific academic queries, the company emphasizes fostering independent learning skills and a sense of responsibility in students, thereby improving their overall confidence in their educational journey.

Aelin Therapeutics is a privately held Belgian biotherapeutics company founded in 2017, based in Heverlee. The company develops antibiotics and therapeutics using its proprietary Pept-in technology, which leverages protein aggregation to induce functional knockdown of target proteins. This approach allows for the rational design of novel biotherapeutics that can address undruggable human targets and combat resistant bacteria like Methicillin-resistant Staphylococcus aureus (MRSA). Aelin Therapeutics' platform offers a unique mode of action and intracellular target space, differentiating it from traditional small molecule drugs or protein-based therapeutics. The company's technology has shown applications in various areas including bacteria, cancer cells, fungi, viruses, and plant cells, with supporting preclinical Proof of Concept data published in high-impact journals such as Science.

Orphazyme is a Copenhagen-based biopharmaceutical company focused on developing innovative therapies for lysosomal storage diseases, a group of serious genetic disorders. The company was founded on research conducted by Professor Marja Jäättela and Thomas Kirkegaard Jensen at the Danish Cancer Society. Orphazyme is engaged in biopharmaceutical research and development, and it has established collaborations with leading academic institutions in Europe and the United States. The company has also entered into a strategic partnership with CombiGene AB, further enhancing its capabilities in the field.

Caiway is a telecom infrastructure company based in Naaldwijk, Netherlands, specializing in broadband connectivity for over 350,000 households and businesses. The company has expanded its operations in recent years by rolling out fiber networks to underserved municipalities and remote areas. As a regional internet service provider, Caiway offers a comprehensive suite of services, including cable television, broadband internet, and telephony, utilizing advanced cable and fiber infrastructure. Key regions within its operational footprint include Westland, Schiedam, and Almelo, where it aims to deliver reliable networking solutions to enhance connectivity for its customers.

Xeltis AG, established in 2006, is a clinical-stage medical device company based in Zurich, Switzerland, with additional operations in the Netherlands and the USA. The company specializes in developing bio-absorbable heart valves and blood vessels using a proprietary polymer-based technology. Xeltis' RestoreX platform enables the body's natural healing system to develop tissue that replaces the implant, forming a new functional valve or vessel. The company's restorative devices include implantable small diameter blood vessels for hemodialysis and coronary artery bypass graft (CABG) surgery, as well as pulmonary heart valves, with ongoing clinical trials. Xeltis has raised funding from various venture capital firms and European institutions, including a €30 million round in 2021.

DentConnect is a fast-growing platform of dental clinics, with activities in the Netherlands, Belgium, Denmark, Germany and Italy. DentConnect is headquartered in the Netherlands and serves over one million patients through its pan-European network of over 220 clinics. DentConnect acts as a multi-functional service organization for these clinics, allowing the dentists to fully focus on providing patients with the best possible care. DentConnect Shared Service Center supports and facilitates dentists with HR, Finance and administration, quality and care management, procurement, marketing and communication and general management.

Two modern and strategically located office buildings in suburban Frankfurt.

Simplify Medical, Inc. is a medical device company specializing in the design, development, manufacturing, and marketing of cervical and lumbar artificial discs intended for spinal use. Founded in 2013 and based in Sunnyvale, California, it offers innovative products such as the Simplify Disc, a non-metallic, MRI-compatible artificial cervical disc that preserves motion while allowing for full diagnostic imaging without the need for traditional CT scans. This technology minimizes patient exposure to ionizing radiation and is tailored for skeletally mature patients undergoing reconstruction at one level from C3 to C7 following discectomy procedures. Simplify Medical markets its products through distributors in the United Kingdom, Germany, and other international markets. The company was previously known as Simplify Delaware, Inc. before rebranding in February 2015.

Open Systems AG, established in 1990 and headquartered in Zurich, Switzerland, specializes in providing comprehensive managed security services to global enterprises, NGOs, and institutions. The company offers a range of services, including network security, application delivery, identity management, and global connectivity, ensuring secure and reliable IT networks and business-critical applications. Open Systems' offerings encompass distributed and enterprise firewall services, WAN encryption, network security monitoring, and incident response, among others. Serving diverse sectors such as finance, healthcare, and government, the company aims to deliver effective security solutions tailored to clients' unique needs.

Cardior Pharmaceuticals GmbH is a biotechnology company based in Hanover, Germany, founded in 2016. The company specializes in developing non-coding RNA-based therapeutics aimed at treating and preventing heart disease, which is the leading cause of death in the western world. Its primary focus is on CDR-132X, an oligonucleotide-based inhibitor that targets a critical microRNA responsible for pathological changes in the heart resulting from stress or injury. Through its innovative approach, Cardior Pharmaceuticals seeks to address significant unmet medical needs in cardiovascular health.

Innovyze is a global provider of software solutions focused on wet infrastructure business analytics, catering to the technological needs of water and wastewater utilities, government agencies, and engineering organizations. The company serves a diverse clientele, including major cities and foremost utilities across the UK, Australia, East Asia, and North America, as well as top-rated design firms worldwide. With a strong presence in North America, Europe, and the Asia Pacific, Innovyze offers a connected portfolio of advanced products that empower engineers to effectively plan, manage, design, protect, operate, and sustain efficient and reliable water infrastructure systems. This comprehensive approach ensures that its clients can achieve optimal performance and enduring success in their operations.

Binx Health Limited is an in vitro diagnostics company based in Trowbridge, United Kingdom, founded in 2005. The company specializes in developing diagnostic instruments and disposable cartridge systems for decentralized laboratory and point-of-care settings. Its flagship product, the binx io platform, is the first FDA-cleared, CLIA-waived system for detecting chlamydia and gonorrhea in both males and females, delivering results comparable to central laboratory performance within approximately thirty minutes. Binx Health aims to enhance healthcare access by addressing traditional barriers and extending outreach through its point-of-care diagnostic solutions. The company also focuses on providing rapid polymerase chain reaction (PCR)-based results and a comprehensive digital program that includes evidence-based testing, counseling, treatment, and follow-up services. Binx Health has established a strategic partnership with Sherlock Biosciences, further strengthening its commitment to improving community health outcomes.

GETEC is a prominent group of energy service providers operating across Germany and Europe, employing nearly 1,400 individuals. The company offers a comprehensive range of energy services in the liberalized energy market, focusing on energy efficiency, system design, and zero emissions. GETEC aims to guide clients through the complexities of the energy landscape by developing tailored solutions that extend beyond traditional energy considerations. Their approach emphasizes sustainability, efficiency, economic viability, and resource conservation, which are fundamental principles of their corporate philosophy. By providing integrated system solutions, GETEC creates added value for clients and supports them in improving their carbon footprint, with a commitment to future generations.

Adamo Telecom is a telecommunications operator based in Spain, specializing in ultra high-speed internet services through Fiber To The Home technology. The company provides internet access with speeds up to 1000 Mbit/s across various regions, including Catalonia, Valencia, Madrid, and Andalucía, among others. Adamo's network coverage extends to numerous provinces such as Alicante, Almería, Asturias, Barcelona, and Sevilla, ensuring connectivity even in remote areas. Originating from Sweden, Adamo aims to deliver high-quality fiber-based access networks and mobile and telephone services to both retail and wholesale subscribers across Europe.

GlobalConnect is a prominent alternative provider of fiber network, data center, and managed hosting services in Northern Europe, primarily focusing on Denmark and Germany. Established in 1998 by Niels Zibrandtsen, the company operates a 12,500 km optical fiber network and manages approximately 13,000 square meters of data center space. GlobalConnect offers a range of services including bandwidth connectivity, colocation, and cloud infrastructure, catering to both enterprises and consumers. With a workforce of over 200 employees, the company is dedicated to delivering fast and reliable networking solutions, enhancing connectivity and technological capabilities for its clients across Sweden, Norway, Denmark, Finland, and Northern Germany.

Independent Vetcare (IVC) is a privately owned veterinary services platform in the UK, boasting over 290 sites and an online pet pharmacy. With a workforce of approximately 2,700 full-time equivalents, including over 800 veterinarians, IVC is dedicated to providing high-quality care for pets across the country.

Fertin Pharma, headquartered in Vejle, Denmark, specializes in the development and production of innovative pharmaceutical and nutraceutical chewing gum products. The company is recognized as a leading B2B partner for nicotine chewing gum, collaborating with prominent global pharmaceutical firms. As a family-owned business with a deep-rooted history in chewing gum, Fertin Pharma manages all aspects of product development and manufacturing. Its extensive portfolio includes oral and intra-oral delivery systems designed to support healthier living, including extruded gum for Nicotine Replacement Therapy and applications in oral care, gastrointestinal health, pain management, and allergy relief. Fertin Pharma is committed to enhancing the effectiveness of active ingredients while ensuring an enjoyable consumer experience through effective taste masking and texture.

GETEC is a prominent group of energy service providers operating across Germany and Europe, employing nearly 1,400 individuals. The company offers a comprehensive range of energy services in the liberalized energy market, focusing on energy efficiency, system design, and zero emissions. GETEC aims to guide clients through the complexities of the energy landscape by developing tailored solutions that extend beyond traditional energy considerations. Their approach emphasizes sustainability, efficiency, economic viability, and resource conservation, which are fundamental principles of their corporate philosophy. By providing integrated system solutions, GETEC creates added value for clients and supports them in improving their carbon footprint, with a commitment to future generations.

Dojo is a financial technology company that specializes in providing card payment solutions to small and medium-sized businesses in the UK and Ireland. The company offers a range of services, including contactless card machines, online payment systems, and integrated solutions, allowing over 100,000 businesses to accept payments in-store, online, via phone, and on the move. Founded in 2008 and based in London, Dojo focuses on delivering flexible and efficient payment processing options tailored to the needs of its clients. The company's offerings aim to enhance the payment experience for both merchants and their customers, thereby facilitating smoother transactions across various platforms.

CHEP is a leading global provider of supply chain solutions, specializing in enhancing efficiency and sustainability for its customers. The company offers a range of services, including asset management and repair for unit load devices (ULDs), galley carts, and ground support equipment through its CHEP Aerospace Solutions division, headquartered in Zurich, Switzerland. This division manages the world's largest independent fleet of ULDs and operates a comprehensive global network for the maintenance and repair of containers, pallets, and inflight food service equipment. By providing tailor-made outsourcing solutions, CHEP enables airlines to focus on their core operations of transporting passengers and cargo while achieving significant cost savings and operational benefits. The company serves over 80 airlines worldwide, leveraging its unique capabilities and insights to help clients improve their logistics and supply chain management.

Vivasure Medical Limited is a medical device company based in Galway, Ireland, that specializes in the research, development, and manufacture of arterial and venous closure devices utilizing its patented PerQseal technology. The company focuses on creating polymer implants and delivery systems aimed at minimally invasive vessel closures, primarily in cardiology, interventional radiology, and vascular surgery. Its flagship product is an absorbable patch-based large-bore percutaneous closure device, designed to effectively close large arteriotomies resulting from transcatheter procedures, including transcatheter aortic valve replacement and endovascular aneurysm repair. Founded in 2008, Vivasure Medical is committed to advancing techniques that enhance patient outcomes in vascular access procedures.

TransIP Group B.V., established in 2003 and headquartered in Leiden, Netherlands, specializes in providing web hosting and related services. It caters primarily to tech-savvy customers and IT professionals, offering a range of products including virtual private servers, domain name registration, and web hosting. The company's notable services comprise BladeVPS PureSSD Pro, a self-managed tool with web control panels and operating systems, STACK for online file storage, syncing, and sharing, and SSL certificates for website encryption. Additionally, TransIP provides services like forwarding, big storage, and private network solutions. As of 2019, TransIP operates as a subsidiary of Combell nv.

Onward is a medical technology company focused on developing therapies aimed at enabling functional recovery for individuals with spinal cord injuries. The company is creating an Implantable Neuro-stimulation System (INS) that features real-time motion feedback and utilizes training tools for rehabilitation. Onward has developed two platforms for neurostimulation: ARCIM, an implantable system, and ARCEX, a non-invasive transcutaneous system. To establish its customer base, Onward has targeted the United States and four European markets, namely Germany, France, the United Kingdom, and the Netherlands.

eTheRNA Immunotherapies NV is a Belgium-based biotechnology company that specializes in the development of mRNA-based immunotherapies. Founded in 2013 and located in Niel, the company focuses on harnessing the immune system's dendritic cells to create treatments for melanoma, triple-negative breast cancer, and infectious diseases. eTheRNA has developed innovative TriMix technology that enhances the immune response, enabling patients to better combat these diseases. The company aims to be a leader in nucleic acid-based medicines, collaborating with partners to facilitate the creation of new drugs and improve patient outcomes. Additionally, eTheRNA has established a strategic partnership with China Grand Pharmaceutical and Healthcare Holdings Limited to further its mission.

kfzteile24 GmbH, established in 2001 and headquartered in Berlin, Germany, is a prominent retailer of automotive spare parts and accessories. The company operates primarily online via its platforms www.kfzteile24.de and www.autoteile24.de, offering a comprehensive range of products such as exhaust systems, axle suspension components, batteries, heaters, interior fittings, and braking systems at competitive prices. To complement its online distribution, kfzteile24 maintains three physical retail stores in Berlin, each with an affiliated repair shop for customer support. The company has experienced continuous growth since its founding, becoming one of Germany's largest online retailers for auto parts and accessories, with sales in the triple-digit million range.

Kuoni Destination Management is a Switzerland-based company that specializes in providing comprehensive destination management services for the travel and hospitality industries. The company focuses on event solutions, offering a range of services that include event development, budgeting, creative direction, and logistical support for virtual, hybrid, and live events. Its expertise encompasses entertainment, audiovisual technology, transportation, and coordination of activities such as gala dinners and public events. Kuoni Destination Management aims to deliver innovative and memorable experiences while ensuring seamless execution and attention to detail in all aspects of event planning and management.

ViCentra B.V., based in Utrecht, the Netherlands, specializes in the development of medical devices, particularly for diabetes management. The company focuses on creating user-friendly and aesthetically pleasing products that aim to enhance the overall experience for individuals managing their health. ViCentra emphasizes the importance of excellent customer experiences and approaches product design with the belief that simplicity and effectiveness lead to better health outcomes. In addition to its operations in the Netherlands, ViCentra also has a presence in the UK, where it continues to innovate in the field of medical devices through dedicated research and development efforts.

Xeltis AG, established in 2006, is a clinical-stage medical device company based in Zurich, Switzerland, with additional operations in the Netherlands and the USA. The company specializes in developing bio-absorbable heart valves and blood vessels using a proprietary polymer-based technology. Xeltis' RestoreX platform enables the body's natural healing system to develop tissue that replaces the implant, forming a new functional valve or vessel. The company's restorative devices include implantable small diameter blood vessels for hemodialysis and coronary artery bypass graft (CABG) surgery, as well as pulmonary heart valves, with ongoing clinical trials. Xeltis has raised funding from various venture capital firms and European institutions, including a €30 million round in 2021.

Sequana Medical is a Swiss medical device company based in Zurich that specializes in developing and commercializing implantable pump systems to manage fluid balance within the body. The company's flagship product, the Alfapump System, is designed to automatically and continually remove ascites, which is excess fluid that accumulates in the abdominal cavity due to advanced liver disease, certain cancers, or congestive heart failure. This system moves the excess fluid to the bladder for natural elimination through urination. Sequana Medical's technology also has potential applications in managing pleural effusions in lung disease patients and fluid overload in those with end-stage renal disease and congestive heart failure. The company was founded in 2006 and has additional offices in Munich, Germany.

kfzteile24 GmbH, established in 2001 and headquartered in Berlin, Germany, is a prominent retailer of automotive spare parts and accessories. The company operates primarily online via its platforms www.kfzteile24.de and www.autoteile24.de, offering a comprehensive range of products such as exhaust systems, axle suspension components, batteries, heaters, interior fittings, and braking systems at competitive prices. To complement its online distribution, kfzteile24 maintains three physical retail stores in Berlin, each with an affiliated repair shop for customer support. The company has experienced continuous growth since its founding, becoming one of Germany's largest online retailers for auto parts and accessories, with sales in the triple-digit million range.

Kuros Biosciences AG is a biopharmaceutical company based in Schlieren, Switzerland, dedicated to the discovery, development, and commercialization of innovative products for tissue repair and regeneration. Founded in 2000 as a spin-off from the Eidgenössische Technische Hochschule Zürich, Kuros has developed a robust pipeline of biopharmaceuticals targeting chronic diseases. Its key products include Neuroseal, a novel biomaterial for dural sealing, and the MagnetOs family of bone graft substitutes used in orthopedic, spinal, and dental applications. MagnetOs is approved for use in the EU and the US, with further formulations under development for regulatory submission. Kuros also has a range of clinical-stage products, including KUR-111 and KUR-113, which have completed Phase II clinical trials for treating specific bone fractures. The company has engaged in significant clinical research, enrolling over 600 patients in multinational trials, generating promising data regarding safety and efficacy in various applications, particularly within orthobiologics.